PCM
TLX

Portolan Capital Management’s Telix Pharmaceuticals TLX Stock Holding History

Portolan Capital Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Sell
25,424
-515,843
-95% -$5.25M 0.01% 146
2026
Q1 		$5.18M Buy
+541,267
New +$4.12M 0.28% 96

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Portolan Capital Management's TLX Position: Q2 2026 in Review

Portolan Capital Management reduced its Telix Pharmaceuticals (TLX) stake by 95% in Q2 2026, selling an estimated $5.25M and leaving 25,424 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #146.

Portolan Capital Management first reported a position in TLX in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.18M in Q1 2026. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Portolan Capital Management held 25,424 shares of Telix Pharmaceuticals worth $293K as of Q2 2026.
  • Portolan Capital Management sold 515,843 Telix Pharmaceuticals shares in Q2 2026, an estimated $5.25M.
  • Telix Pharmaceuticals made up 0.01% of Portolan Capital Management's portfolio in Q2 2026, its #146 holding.
  • Portolan Capital Management first reported a position in Telix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Portolan Capital Management's Telix Pharmaceuticals position peaked at $5.18M in Q1 2026.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Portolan Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.